AI Article Synopsis
- Researchers developed gGlu-HMRG as a fluorescent probe to detect live cancer cells by utilizing the overexpression of the enzyme GGT in cancer versus normal tissue.
- In a study, they tested this probe during breast-conserving surgery and found it could distinguish tumors as small as 1 mm with 92% sensitivity and 94% specificity in just 5 minutes.
- The method is considered a significant advancement in quickly and affordably assessing surgical margins to ensure all cancerous tissue is removed.
Article Abstract
We previously developed γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG) as a tool to detect viable cancer cells, based on the fact that the enzyme γ-glutamyltranspeptidase (GGT) is overexpressed on membranes of various cancer cells, but is not expressed in normal tissue. Cleavage of the probe by GGT generates green fluorescence. Here, we examined the feasibility of clinical application of gGlu-HMRG during breast-conserving surgery. We found that fluorescence derived from cleavage of gGlu-HMRG allowed easy discrimination of breast tumors, even those smaller than 1 mm in size, from normal mammary gland tissues, with 92% sensitivity and 94% specificity, within only 5 min after application. We believe this rapid, low-cost method represents a breakthrough in intraoperative margin assessment during breast-conserving surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499838 | PMC |
| http://dx.doi.org/10.1038/srep12080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!